MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Incyte Corp

Închisă

SectorSănătate

67.8 -1.58

Rezumat

Modificarea prețului

24h

Curent

Minim

67.69

Maxim

68.94

Indicatori cheie

By Trading Economics

Venit

-43M

158M

Vânzări

-126M

1.1B

P/E

Medie Sector

349.9

39.857

EPS

1.16

Marjă de profit

15.025

Angajați

2,617

EBITDA

-80M

257M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+14.98% upside

Dividende

By Dow Jones

Următoarele câștiguri

29 iul. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-2.5B

14B

Deschiderea anterioară

69.38

Închiderea anterioară

67.8

Sentimentul știrilor

By Acuity

41%

59%

150 / 376 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

Incyte Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

17 iul. 2025, 23:34 UTC

Achiziții, Fuziuni, Preluări

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

17 iul. 2025, 21:14 UTC

Achiziții, Fuziuni, Preluări

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

17 iul. 2025, 21:04 UTC

Principalele dinamici ale pieței
Achiziții, Fuziuni, Preluări

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

17 iul. 2025, 23:43 UTC

Market Talk

Gold Edges Higher on Possible Position Adjustments -- Market Talk

17 iul. 2025, 23:42 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

17 iul. 2025, 22:47 UTC

Achiziții, Fuziuni, Preluări

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

17 iul. 2025, 22:46 UTC

Achiziții, Fuziuni, Preluări

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

17 iul. 2025, 22:46 UTC

Achiziții, Fuziuni, Preluări

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

17 iul. 2025, 22:43 UTC

Achiziții, Fuziuni, Preluări

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

17 iul. 2025, 22:43 UTC

Achiziții, Fuziuni, Preluări

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

17 iul. 2025, 22:40 UTC

Achiziții, Fuziuni, Preluări

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 iul. 2025, 22:40 UTC

Achiziții, Fuziuni, Preluări

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 iul. 2025, 22:30 UTC

Market Talk
Câștiguri

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

17 iul. 2025, 22:20 UTC

Market Talk
Câștiguri

Global Equities Roundup: Market Talk

17 iul. 2025, 22:20 UTC

Market Talk
Câștiguri

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

17 iul. 2025, 22:04 UTC

Market Talk
Câștiguri

Netflix Redesign Done to Match Current Capabilities -- Market Talk

17 iul. 2025, 22:03 UTC

Achiziții, Fuziuni, Preluări

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

17 iul. 2025, 21:58 UTC

Market Talk
Câștiguri

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

17 iul. 2025, 21:57 UTC

Câștiguri

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 iul. 2025, 21:47 UTC

Câștiguri

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

17 iul. 2025, 21:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 iul. 2025, 21:45 UTC

Market Talk

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

17 iul. 2025, 21:38 UTC

Achiziții, Fuziuni, Preluări

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

17 iul. 2025, 21:22 UTC

Achiziții, Fuziuni, Preluări

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 iul. 2025, 21:05 UTC

Câștiguri

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 iul. 2025, 21:04 UTC

Achiziții, Fuziuni, Preluări

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

17 iul. 2025, 21:02 UTC

Achiziții, Fuziuni, Preluări

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 iul. 2025, 20:59 UTC

Achiziții, Fuziuni, Preluări

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

17 iul. 2025, 20:50 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

17 iul. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Comparație

Modificare preț

Incyte Corp Așteptări

Obiectiv de preț

By TipRanks

14.98% sus

Prognoză pe 12 luni

Medie 79.6 USD  14.98%

Maxim 107 USD

Minim 52 USD

În baza a 17 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruIncyte Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

17 ratings

7

Cumpărare

9

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

59.52 / 62.66Suport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

150 / 376 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation